Shares of REGENXBIO Inc. (NASDAQ:RGNX) have earned a consensus broker rating score of 1.17 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. REGENXBIO’s rating score has declined by 3.5% from 90 days ago as a result of various analysts’ upgrades and downgrades.
Brokerages have set a twelve-month consensus price objective of $37.00 for the company and are expecting that the company will post ($0.81) EPS for the current quarter, according to Zacks. Zacks has also assigned REGENXBIO an industry rank of 123 out of 265 based on the ratings given to its competitors.
Several equities research analysts have recently commented on RGNX shares. Chardan Capital upped their price target on REGENXBIO from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, April 11th. Zacks Investment Research upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research note on Saturday, April 15th. Finally, TheStreet cut REGENXBIO from a “c-” rating to a “d+” rating in a research note on Friday, April 7th.
In other REGENXBIO news, insider Kenneth T. Mills sold 6,500 shares of the stock in a transaction on Tuesday, June 20th. The stock was sold at an average price of $19.68, for a total value of $127,920.00. Following the completion of the transaction, the insider now owns 119,396 shares in the company, valued at $2,349,713.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Vittal Vasista sold 3,100 shares of the stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $18.75, for a total value of $58,125.00. Following the completion of the transaction, the chief financial officer now owns 107,512 shares of the company’s stock, valued at approximately $2,015,850. The disclosure for this sale can be found here. Insiders sold 19,200 shares of company stock valued at $368,746 in the last quarter. 17.00% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Redmile Group LLC acquired a new position in REGENXBIO during the first quarter valued at about $24,494,000. Citadel Advisors LLC boosted its position in REGENXBIO by 625.1% in the first quarter. Citadel Advisors LLC now owns 559,887 shares of the biotechnology company’s stock valued at $10,806,000 after buying an additional 482,667 shares during the last quarter. Vanguard Group Inc. boosted its position in REGENXBIO by 23.2% in the first quarter. Vanguard Group Inc. now owns 981,517 shares of the biotechnology company’s stock valued at $18,942,000 after buying an additional 184,700 shares during the last quarter. JPMorgan Chase & Co. boosted its position in REGENXBIO by 17.6% in the first quarter. JPMorgan Chase & Co. now owns 1,175,794 shares of the biotechnology company’s stock valued at $22,693,000 after buying an additional 176,047 shares during the last quarter. Finally, UBS Oconnor LLC acquired a new position in REGENXBIO during the first quarter valued at about $2,575,000. Hedge funds and other institutional investors own 67.24% of the company’s stock.
REGENXBIO (NASDAQ RGNX) traded up 2.22% during trading on Thursday, reaching $18.40. 124,479 shares of the company’s stock were exchanged. The stock’s market capitalization is $567.11 million. REGENXBIO has a 52 week low of $8.08 and a 52 week high of $24.55. The stock has a 50-day moving average of $19.75 and a 200-day moving average of $19.36.
REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by $0.06. REGENXBIO had a negative return on equity of 39.52% and a negative net margin of 1,595.18%. The company had revenue of $0.46 million for the quarter. On average, equities research analysts anticipate that REGENXBIO will post ($3.12) EPS for the current year.
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.